MOUNJARO 5MG KWIK PEN ( Tirzepatide 5 mg)

Composition
Each prefilled pen contains Tirzepatide 5 mg as a sterile solution for subcutaneous injection.

Description
MOUNJARO 5 mg Pen is an antidiabetic injectable medicine indicated for the treatment of type 2 diabetes mellitus. Tirzepatide is a dual GIP and GLP-1 receptor agonist that helps improve glycaemic control by enhancing glucose-dependent insulin secretion, suppressing excess glucagon release, slowing gastric emptying and reducing appetite. This results in effective blood sugar control and supports weight reduction when combined with appropriate diet and lifestyle measures.

Adverse Effects
Common adverse effects include nausea, vomiting, diarrhoea, constipation, abdominal discomfort and reduced appetite, particularly during the initial weeks of therapy. Injection site reactions such as pain, redness or itching may occur. Hypoglycaemia can occur, especially when used along with insulin or sulfonylureas.

Precautions
MOUNJARO is intended for subcutaneous administration only and should not be given intravenously or intramuscularly. Caution is advised in patients with a history of pancreatitis, severe gastrointestinal disorders or thyroid disease. Dose escalation should be done gradually to minimise gastrointestinal side effects. Use during pregnancy or breastfeeding should be only under medical supervision. Regular monitoring of blood glucose levels is recommended.

Storage
Store refrigerated between 2°C and 8°C. Do not freeze. Protect from light. After first use, store as per manufacturer’s instructions. Keep out of reach of children.